Notice2025-15556
Revocation of Authorization of Emergency Use of In Vitro Diagnostic Device for Detection and/or Diagnosis of COVID-19; Availability
Primary source
Metadata and text below are from the Federal Register, a public-domain U.S. government work. Always verify the official published version before relying on it for any legal matter.
Published
August 15, 2025
Effective
April 15, 2025
Issuing agencies
Health and Human Services DepartmentFood and Drug Administration
Abstract
The Food and Drug Administration (FDA) is announcing the revocation of the Emergency Use Authorization (EUA) (the Authorization) issued to LumiraDx UK Ltd. for the LumiraDx SARS CoV-2 RNA STAR Complete. FDA revoked the Authorization under the Federal Food, Drug, and Cosmetic Act (FD&C Act) as requested by the Authorization holder. The revocation, which includes an explanation of the reason for revocation, is reprinted at the end of this document.
Full Text
<html>
<head>
<title>Federal Register, Volume 90 Issue 156 (Friday, August 15, 2025)</title>
</head>
<body><pre>
[Federal Register Volume 90, Number 156 (Friday, August 15, 2025)]
[Notices]
[Pages 39394-39395]
From the Federal Register Online via the Government Publishing Office [<a href="http://www.gpo.gov">www.gpo.gov</a>]
[FR Doc No: 2025-15556]
-----------------------------------------------------------------------
DEPARTMENT OF HEALTH AND HUMAN SERVICES
Food and Drug Administration
[Docket No. FDA-2022-N-0150]
Revocation of Authorization of Emergency Use of In Vitro
Diagnostic Device for Detection and/or Diagnosis of COVID-19;
Availability
AGENCY: Food and Drug Administration, HHS.
ACTION: Notice.
-----------------------------------------------------------------------
SUMMARY: The Food and Drug Administration (FDA) is announcing the
revocation of the Emergency Use Authorization (EUA) (the Authorization)
issued to LumiraDx UK Ltd. for the LumiraDx SARS CoV-2 RNA STAR
Complete. FDA revoked the Authorization under the Federal Food, Drug,
and Cosmetic Act (FD&C Act) as requested by the Authorization holder.
The revocation, which includes an explanation of the reason for
revocation, is reprinted at the end of this document.
DATES: The revocation of the Authorization for the LumiraDx UK Ltd.'s
LumiraDx SARS CoV-2 RNA STAR Complete was effective as of April 15,
2025.
ADDRESSES: Submit written requests for a single copy of the revocation
to the Office of Policy, Center for Devices and Radiological Health,
Food and Drug Administration, 10903 New Hampshire Ave., Bldg. 66, Rm.
5441, Silver Spring, MD 20993-0002. Send one self-addressed adhesive
label to assist that office in processing your request or include a fax
number to which the revocation may be sent. See the SUPPLEMENTARY
INFORMATION section for electronic access to the revocation.
FOR FURTHER INFORMATION CONTACT: Kim Sapsford-Medintz, Office of
Product Evaluation and Quality, Center for Devices and Radiological
Health, Food and Drug Administration, 10903 New Hampshire Ave., Bldg.
66, Rm. 3216, Silver Spring, MD 20993-0002, 301-796-0311 (this is not a
toll-free number).
SUPPLEMENTARY INFORMATION:
I. Background
Section 564 of the FD&C Act (21 U.S.C. 360bbb-3) as amended by the
Project BioShield Act of 2004 (Pub. L. 108-276) and the Pandemic and
All-Hazards Preparedness Reauthorization Act of 2013 (Pub. L. 113-5)
allows FDA to strengthen the public health protections against
biological, chemical, radiological, or nuclear agent or agents. Among
other things, section 564 of the FD&C Act allows FDA to authorize the
use of an unapproved medical product or an unapproved use of an
approved medical product in certain situations.
On October 14, 2020, FDA issued the Authorization to LumiraDx UK
Ltd. for the LumiraDx SARS CoV-2 RNA STAR Complete, subject to the
terms of the Authorization. Notice of the issuance of this
Authorization was published in the Federal Register on April 23, 2021
(86 FR 21749), as required by section 564(h)(1) of the FD&C Act.
Subsequent updates to the Authorization were made available on
FDA's website. The authorization of a device for emergency use under
section 564 of the FD&C Act may, pursuant to section 564(g)(2) of the
FD&C Act, be revoked when the criteria under section 564(c) of the FD&C
Act for issuance of such authorization are no longer met (section
564(g)(2)(B) of the FD&C Act), or other circumstances make such
revocation appropriate to protect the public health or safety (section
564(g)(2)(C) of the FD&C Act).
II. Authorization Revocation Request
In a request received by FDA on November 8, 2024, LumiraDx UK Ltd.
requested the revocation of, and on April 15, 2025, FDA revoked, the
Authorization for the LumiraDx UK Ltd.'s LumiraDx SARS CoV-2 RNA STAR
Complete. LumiraDx UK Ltd. notified FDA that they have ceased
manufacture of the authorized product, and requested FDA revoke the
LumiraDx UK Ltd.'s LumiraDx SARS CoV-2 RNA STAR Complete. FDA has
determined that it is appropriate to protect the public health or
safety to revoke this Authorization.
III. Electronic Access
An electronic version of this document and the full text of the
revocation is available on the internet at <a href="https://www.regulations.gov/">https://www.regulations.gov/</a>.
IV. The Revocation
Having concluded that the criteria for revocation of the
Authorization under section 564(g)(2)(C) of the FD&C Act are met, FDA
has revoked the EUA for LumiraDx UK Ltd.'s LumiraDx SARS CoV-2 RNA STAR
Complete. The revocation in its entirety follows and provide an
explanation of the reason for revocation, as required by section
564(h)(1) of the FD&C Act.
BILLING CODE 4164-01-P
[[Page 39395]]
[GRAPHIC] [TIFF OMITTED] TN15AU25.011
Dated: August 11, 2025.
Grace R. Graham,
Deputy Commissioner for Policy, Legislation, and International Affairs.
[FR Doc. 2025-15556 Filed 8-14-25; 8:45 am]
BILLING CODE 4164-01-C
</pre></body>
</html>Indexed from Federal Register on August 15, 2025.
This is legal information, not legal advice. Laws vary by jurisdiction and change frequently. Always verify current law with official sources and consult a licensed attorney in your jurisdiction for advice on your specific situation.